Variation in Coverage of Atopic Dermatitis Therapies Across Commercial Payers

This economic evaluation examines the diagnostic threshold, step therapy, and prescriber requirements from commercial health plans for covering 7 US Food and Drug Administration–approved atopic dermatitis medications.

Corresponding Author: James D. Chambers, PhD, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111 (jchambers@tuftsmedicalcenter.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.